Table 4.

The relative risk (RR) of the different tests.

	Development of ZCL					Severity of the disease
	Cut-off	N	+/−a	+ZCL/−ZCLb	RRc	p	N	+/−a	Sv/–ZCL d	RRc	p
LST	5mm	453	167/286	90/363	0.85	0.466	402	144/258	39/363	0.392*	0.009*
Scar	–	453	105/348	90/363	0.713	0.209	402	93/309	39/363	0.38*	0.047*
Grz B	2 ng/mL	453	138/315	90/363	0.78	0.306	402	119/283	39/363	0.272*	0.003*

^aNumber of subject positive for the test/Number of individuals negative for the test.

^bNumber of subject who developed ZCL lesions/Number of subjects without any ZCL lesion.

^cRR, Relative Risk, RR < 1 indicates a decrease in the risk of ZCL and vice versa.

^dNumber of subject who developed an intermediate or severe ZCL (Sv)/Number of subjects without any ZCL lesion.

^*Statistically significant (p < 0.05)

N, Number of tested subjects; LST, Leishmanin Skin Test; Scar +/−, presence/absence of ZCL scar; GrzB +/−, Grz B level ≥2 ng/ml or <2 ng/ml.

+/−Corresponding to the number of subject positive for the test/Number of subject negative for the test.